Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy

Summary

Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis and cardiomyopathy. Currently, only limited data on serial myocardial tissue changes during treatment and whether they predict outcomes are available. Cardiac MRI (CMR) is the reference standard for non-invasive myocardial volumes/function analysis and uniquely characterizes myocardial tissue. Therefore, it may help detect myocardial tissue changes during treatment and help early treatment and prevent adverse cardiac outcomes.

Eligibility

Inclusion Criteria:

* All patients 18 years of age, or older, with skin cancer and eligible for ICI treatment with a combination of a) nivolumab, b) pembrolizumab, or c) ipilimumab.
* Able to provide informed consent
* Able to travel to SHSC for cardiac imaging.

Exclusion Criteria:

* Life expectancy equal to, or less than, 12 months
* Participating in another clinical trial
* Treated with ICI in the past
* History of cardiac disease (e.g. heart failure, myocardial infarction, atrial fibrillation, unstable angina)
* Pregnant patients
* Impaired renal function (GFR equal to, or less than, 30mL/min)
* Contraindications for MRI (e.g. pacemaker).

Conditions4

Browse More Trials